14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DNTH vs PVLA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). DNTH carries a Unified Composite Score of 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. 0.0% operating margin) and revenue trajectory (+205.6% vs. +0.0% YoY).
Competes within the Biotechnology value chain with $2.2B market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ DNTH vs PVLA Key Questions & Quantitative Answers
As of Nov 16, 2026, Dianthus Therapeutics, Inc. (DNTH) is the stronger overall head-to-head candidate over Palvella Therapeutics, Inc. (PVLA) in the Tradestie Institutional Equity Comparison Engine, winning 4–3 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). DNTH carries a Unified Composite Score of 34.1/100 (SELL) at $88.58 (N/M Forward P/E, -8683.9% operating margin), whereas PVLA carries 48.2/100 (HOLD) at $145.03 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While PVLA currently prints a higher short-term Unified Composite Score (48.2/100 HOLD vs. DNTH 34.1/100 SELL), DNTH captures the overall institutional head-to-head verdict (4–3 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-8683.9% vs. 0.0% operating margin) and revenue trajectory (+205.6% vs. +0.0% YoY).
DNTH leads the Growth & Scale pillar: DNTH posts +205.6% YoY revenue growth and +0.0% YoY earnings growth on $2.7M TTM revenue (100.0% gross margin, -8683.9% operating margin), compared with PVLA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DNTH cumulative revenue shifted N/A while PVLA shifted +33.3%. In operating R&D and SG&A reinvestment, DNTH deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PVLA.
DNTH and PVLA trade at balanced relative valuation multiples. DNTH trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas PVLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DNTH (-22.6% ROE) versus PVLA (-63.4% ROE) capital efficiency.
In options market volatility and institutional positioning, DNTH carries 83.5% implied volatility (7th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.03β · 41% Vol realized risk). By comparison, PVLA carries 47.9% implied volatility (2nd %ile, Compressed (<25th %ile)), a 3.82x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.66β · 75% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.